Amalgamated Bank Cyma Bay Therapeutics, Inc. Transaction History

Amalgamated Bank

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$12.63 - $24.47 $17,783 - $34,453	1,408 Added 9.47%	16,279 $385,000
Q2 2023 Aug 11, 2023	BUY	$7.47 - $10.95 $111,086 - $162,837	14,871 New	14,871 $162,000
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $14,415 - $28,411	-8,381 Closed	0 $0
Q1 2022 Jun 30, 2022	BUY	$2.77 - $3.64 $23,215 - $30,506	8,381 New	8,381 $26,000
Q2 2020 Aug 10, 2020	SELL	$1.41 - $4.25 $17,214 - $51,888	-12,209 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$1.25 - $2.02 $135 - $218	108 Added 0.89%	12,209 $18,000
Q4 2019 Feb 13, 2020	SELL	$1.33 - $5.93 $39 - $177	-30 Reduced 0.25%	12,101 $24,000
Q3 2019 Nov 13, 2019	SELL	$5.12 - $7.21 $450 - $634	-88 Reduced 0.72%	12,131 $62,000
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $73,924 - $166,911	12,219 New	12,219 $87,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.